Welcome to the IDT family!

Your product is now available from Integrated DNA Technologies.

Many of the Swift products you have grown to love are now part of our new complete portfolio, xGen™ NGS. Through this new partnership we are pleased to offer you comprehensive next generation sequencing solutions.

xGen NGS—made for you.

Unsure of what products are available? Or, perhaps you’d like guidance on which products are compatible? If so, try our xGen NGS Solutions Builder Tool today.

Welcome to the IDT family!

Find Archer now at IDT!

All Archer information is now available on IDT’s website. You can view Archer assays alongside IDT’s xGen™ NGS portfolio to find the best next generation sequencing solution for your lab.

Confidently detect more with Archer NGS assay solutions for your solid tumor, blood cancer, immune profiling, and genetic disease research.

  • CRISPR knock-in: Tips and tricks

    Nov 28, 2023, 16:26 PM
  • Overcome challenges in cancer research with IDT’s xGen™ NGS solutions for oncology and MRD research

    Nov 9, 2023, 21:41 PM
  • Unveiling the potential of CRISPR: A guide to gene editing

    Oct 27, 2023, 14:44 PM
  • Custom CRISPR solutions for high-throughput workflows

    Sep 26, 2023, 18:35 PM
  • Unlocking the potential of ultra-low frequency variant identification for cancer research

    Sep 26, 2023, 18:25 PM
  • How to design antisense oligonucleotides (ASOs) for high on-target potency and minimal off-target effect

    Jul 12, 2023, 19:30 PM
  • Novel identification in diverse sample types through direct amplification

    Jun 15, 2023, 18:27 PM
  • ctDNA for minimal disease research by hybridization capture in resected cancer samples

    Apr 19, 2023, 15:59 PM
  • How to optimize CRISPR genome editing in primary T cells

    Mar 15, 2023, 15:42 PM
  • The future of personalized genomics: advancing hematology research with NGS

    Feb 15, 2023, 19:19 PM
  • Enabling faster therapeutic antibody discovery through an integrated AI/ML-wet lab platform

    Feb 1, 2023, 19:31 PM
  • One-step qPCR master mix for amplification from crude or purified samples

    Jan 3, 2023, 15:23 PM
  • Pan-cancer pharmacogenetics: Targeted sequencing panels or exome sequencing?

    Nov 3, 2022, 18:18 PM
  • The power of whole exome sequencing to unravel the cause of rare disease

    Nov 3, 2022, 18:16 PM
  • Whole exome sequencing reveals timing and origins of local and distant metastasis in lung cancer

    Nov 3, 2022, 18:15 PM
  • M2GEN’s ORIEN Avatar program accelerates oncology research with a custom xGen Exome Research Panel

    Nov 3, 2022, 18:13 PM
  • The history & future of whole exome sequencing at the McDonnell Genome Institute

    Nov 3, 2022, 17:42 PM
  • Overcome cancer research challenges with NGS solutions

    Oct 6, 2022, 21:08 PM
  • Building one of the nation’s leading COVID-19 surveillance programs

    Oct 5, 2022, 21:11 PM
  • Tackling infectious disease surveillance challenges

    Oct 5, 2022, 20:52 PM
  • 1
  • 2 (current)
  • 3
  • 4